German biotech company CureVac sued Moderna (NASDAQ:MRNA) in Delaware federal court on Friday, alleging that Moderna’s COVID-19 vaccine Spikevax infringed CureVac patents related to messenger RNA technology.
CureVac said in the lawsuit that Moderna copied its technology for stabilizing fragile mRNA to use in vaccines and requested royalties from Moderna’s Spikevax sales in damages.
Germany-based BioNTech (OTC:22UAy), which partnered with Pfizer (NYSE:PFE) to create the competing COVID-19 vaccine Comirnaty, acquired CureVac last year. BioNTech filed a separate U.S. patent lawsuit against Moderna over its next-generation mNEXSPIKE COVID-19 shot in February.
Moderna said in a statement that it was aware of the lawsuit filed on Friday and will defend itself. Spokespeople for CureVac and BioNTech did not immediately respond to requests for comment on the lawsuit.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.